TTOO Logo

T2 Biosystems, Inc. (TTOO) 

NASDAQ
Market Cap
$12.15M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
747 of 776
Rank in Industry
41 of 42

Largest Insider Buys in Sector

TTOO Stock Price History Chart

TTOO Stock Performance

About T2 Biosystems, Inc.

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream …

Insider Activity of T2 Biosystems, Inc.

Over the last 12 months, insiders at T2 Biosystems, Inc. have bought $0 and sold $133 worth of T2 Biosystems, Inc. stock.

On average, over the past 5 years, insiders at T2 Biosystems, Inc. have bought $47,937 and sold $2.48M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 12,952 shares for transaction amount of $6,476 was made by Barclay Alec (Chief Operations Officer) on 2022‑04‑08.

List of Insider Buy and Sell Transactions, T2 Biosystems, Inc.

2024-09-13Saledirector
55
0.0003%
$2.42$133-36.96%
2023-09-28Sale10 percent owner
1.94M
0.5132%
$0.16$305,212-5.51%
2023-09-27Sale10 percent owner
5.98M
1.8991%
$0.19$1.15M-5.51%
2023-09-26Sale10 percent owner
5.39M
1.5921%
$0.20$1.08M-5.51%
2023-09-25Sale10 percent owner
250,000
0.0854%
$0.25$62,500-5.51%
2023-09-22Sale10 percent owner
5.08M
1.5515%
$0.26$1.31M-5.51%
2023-09-21Sale10 percent owner
6.34M
1.9818%
$0.30$1.9M-5.51%
2023-09-20Sale10 percent owner
7.75M
2.393%
$0.31$2.41M-5.51%
2023-09-19Sale10 percent owner
10.4M
3.3665%
$0.37$3.81M-5.51%
2023-03-28SaleGeneral Counsel
239
<0.0001%
$0.48$115-5.51%
2023-02-28SaleChairman and CEO
2,898
<0.0001%
$0.59$1,710-5.51%
2023-02-28SaleChief Financial Officer
1,148
<0.0001%
$0.59$677-5.51%
2023-02-28SaleGeneral Counsel
1,585
<0.0001%
$0.59$935-5.51%
2023-02-22SaleChairman and CEO
6,875
<0.0001%
$0.65$4,469-5.51%
2023-02-22SaleChief Financial Officer
1,545
<0.0001%
$0.65$1,004-5.51%
2023-02-22SaleGeneral Counsel
2,145
<0.0001%
$0.65$1,394-5.51%
2023-02-22SaleChief Commercial Officer
537
<0.0001%
$0.65$349-5.51%
2023-02-20SaleChief Commercial Officer
537
<0.0001%
$0.65$349-5.51%
2022-11-10SaleChief Commercial Officer
1,292
0.0246%
$1.79$2,317
2022-04-08PurchaseChief Operations Officer
12,951.88
0.0076%
$0.50$6,476-81.61%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$137,085.000.345,6950%+$0<0.0001
Susquehanna International Group$123,498.000.2741,166-25.16%-$41,514.00<0.0001
BlackRock$110,883.000.2436,9610%+$0<0.0001
Geode Capital Management$83,538.000.1827,840+15.74%+$11,360.45<0.0001
Virtu Financial Llc$39,000.000.0913,096+29.95%+$8,987.63<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.